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Introduction: Cachexia is associated with rheumatoid arthritis (RA), but whether it is 
attributable primarily to reduced dietary intake or increased metabolism is unclear, as is the 
association with inflammation. To examine whether rheumatoid cachexia is related to increased 
energy expenditure, reduced food intake, or an inflammatory cytokine response we undertook 
a prospective, longitudinal study of patients with RA, during periods of relative relapse and 
remission of inflammation.
Methods: Sixteen patients admitted to hospital with a flare of RA were assessed clinically to 
determine disease activity and were re-examined 6 weeks later. Their fat-free mass (FFM), dietary 
intake, resting energy expenditure (REE), and plasma concentrations of interleukin-6 (IL-6) 
were also measured. Data were compared with those from 16 healthy, age- and   sex-matched 
controls.
Results: At baseline the body weight, body mass index, and FFM of patients with RA were 
significantly lower than those of controls. Disease activity scores of patients (6.39 ± 0.8) were 
reduced when the patients were re-examined 6 weeks later (5.23 ± 1.26) and FFM was no 
longer statistically different from that of controls (visit 1 = 25.8 ± 10.1 and visit 2 = 26.8 ± 9.5 
versus controls = 32.3 ± 10.9). There were no differences in food intake between patients and 
controls or between patients studied at the 2 time points, but REE was greater in patients after 
correcting for FMM (visit 1 = 62.2 ± 24.7, visit 2 = 59.7 ± 26.3 versus controls = 46.0 ± 13.7). 
Plasma IL-6 concentrations were significantly higher in patients than controls. Although IL-6 
was not significantly correlated with REE, lower REE measurements were not observed when 
the plasma IL-6 concentration increased.
Conclusion: Reduced FFM in patients with RA is not attributable to reduced food intake. Energy 
expenditure is greater in patients when corrected for FFM, particularly in patients with acute 
flares of disease activity. Although clearly not the only factor involved, increased production of 
IL-6 may contribute to increasing REE.
Keywords: rheumatoid arthritis, cachexia, free-fat mass, fat mass, resting energy expenditure, 
interleukin-6
Introduction
Weight loss in individuals with rheumatoid arthritis (RA) has been recognized since 
early observations of the disease.1 More recent studies have indicated that a moderate 
degree of cachexia may be present in a substantial number of patients with RA.2,3 
As with the cachexia associated with cancer or infection, underlying mechanisms are 
uncertain. Data from studies of RA have suggested that tumor necrosis factor alpha 
(TNF-α) or interleukin-1 (IL-1) might be important in the cachexia associated with RA.4 
These cytokines are, however, rarely found in plasma, although increased plasma IL-6 is Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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commonly found in patients with arthritis and concentrations 
are related to inflammatory activity.5–7 IL-6 is induced by 
IL-1 and TNF-α8 and has important   systemic functions in 
inflammation.8 It has been implicated in   animal models of 
cachexia9–11 and in patients with cancer12,13 although its link 
to cachexia in RA is unclear.
RA is characterized by a remitting and relapsing clinical 
course. It therefore seemed reasonable to hypothesize that the 
mechanism(s) responsible for cachexia would be activated 
most clearly during periods of increased disease activity. 
Previous studies have been of a cross-sectional nature and 
have not been able to directly address this possibility.2–4 
We therefore set out to examine whether cachexia in RA 
was associated with increased energy expenditure and/or 
reduced food intake, or with plasma IL-6 concentrations, in 
a prospective, longitudinal study of patients with RA, during 
periods of relative relapse and remission.
Materials and methods
Sixteen adult patients with active joint disease and RA, 
as defined by the revised criteria of the American Rheu-
matology Association14 were admitted under the care of 
the rheumatological rehabilitation services of Ladywell 
Hospital, Salford, for treatment of an increase in disease 
activity. All patients were Caucasian and were age- and 
sex-matched (4 male:12 female mean age 52 ± 14.9 years) 
with 16 apparently healthy control subjects (4 male:12 
female, mean age 51 ± 11.9 years). Each patient was 
studied within 48 hours of hospital admission and then 
again 6 weeks later. Eight patients were taking oral ste-
roids during the study time. Patients with concurrent or 
chronic infection, other inflammatory conditions, condi-
tions primarily associated with weight change (malignancy, 
thyroid disease, diabetes mellitus, congestive cardiac 
failure, pregnancy), or taking medication known to affect 
metabolic rate (thyroxine, β-blockers or β-agonists) were 
excluded from the study.
clinical assessment
All patients were assessed clinically on first and second 
visits using the following measures: 1) Disease activity was 
  measured using the 28-joint-based disease activity score 
(DAS);15 2) morning stiffness in hours; 3) physician’s global 
assessment of disease activity, graded on a scale of 1–5, where 
1 = asymptomatic and 5 = very severe;16 4) patient assessment 
of joint pain and disease activity using a visual analog scale;16 
5) the modified health assessment   questionnaire (mHAQ);17 
6) the visual analog scale for pain.18 A single assessor 
  conducted all clinical examination and scoring.
Anthropometric measurement
Height was measured to the nearest 5 mm using a wall-
mounted stadiometer (Seca, Birmingham, UK), with the 
subject standing erect without shoes. Weight was measured 
to the nearest 0.025 kg, using a calibrated Avery beam 
  balance (Avery Ltd. Birmingham, UK). Skinfold thick-
ness was measured with Harpenden calipers (Holtain Ltd, 
Crymych, UK), at 4 sites (biceps, triceps, suprailiac, and 
subscapular) and percentage body fat was calculated using 
the technique of Durnin and Womersley.19 Fat mass (FM) 
and fat-free body mass (FFM) were calculated using the 
Durnin and Womersley standard tables. Body mass index 
(BMI) was calculated using the formula: weight/(height)2. 
One individual, trained in the techniques, performed all 
anthropometric measurements.
energy metabolism
Resting energy expenditure (REE) was measured by 
  continuous open circuit indirect calorimetry, using a Delta-
trac metabolic monitor (Datex Ltd, Helsinki, Finland).20 The 
system was validated with quantitative alcohol combustion 
prior to use and returned at least 98% of predicted values. On 
the morning of each assessment the system was calibrated 
with the manufacturer’s recommended gases. All measure-
ments were performed between 08:00 and 08:30 hours, 
after a 10- to 12-hour fast. Measurements were made after 
a 30-minute period of rest, with the subject lightly clothed 
and awake, breathing room air quietly in a supine position. 
Oxygen consumption (VO2) and carbon dioxide production 
(VCO2) were measured for 30 minutes and the mean values 
used in subsequent calculations. VO2 and VCO2 were used to 
calculate REE, employing the formula of Weir.20
Dietary intake
Each patient’s dietary intake was calculated by evaluating 7, 
nonconsecutive, self-administered, 24-hour dietary histories 
over the 6-week period between the 2 assessment visits for 
patients and over the same period for the controls. Dietary 
analysis was carried out by entering types and quantities of 
food consumed into ‘Microdiet’ software (Salford University, 
Salford, UK), using McCance and Widdowson’s   composition 
of food tables.22 Energy content was calculated for patients 
and controls. Protein intake per kg body weight was calculated 
using 24-hour urinary nitrogen measurements.23Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Laboratory measurements
Urinary nitrogen content was measured by an automated 
micro-Kjeldahl technique (Foss Electric, Copenhagen).24 
Plasma IL-6 concentrations and C-reactive protein (CRP) 
were measured by enzyme-linked immunosorbant assays, as 
described by Holt et al.25 The erythrocyte sedimentation rate 
(ESR) was determined by the Westergren method.
statistical analysis
All reported values are means ± SD, or median with range, 
and comparisons between groups (cases and controls) were 
analyzed using a t test or a Mann–Whitney test,   depending 
on their distribution. For within-group analysis with 
  normally distributed values, a paired t test was used, and for 
the   nonparametric data a Wilcoxon rank test was applied. 
A bivariate correlation analysis (Spearman) was used to 
study the association between anthropometric variables and 
IL-6. A P value ,0.05 was chosen as indicative of statistical 
significance. Comparison of REE and food intake between 
patients and controls, and the relationship between IL-6 and 
(REE) were primary outcome measures. All other analyses 
were secondary and exploratory.
Results
Disease activity
Disease activity in patients was significantly reduced at the 
second visit for morning stiffness, DAS 28 score, physician’s 
assessment of disease activity, and mHAQ (Table 1). Mean 
ESR, CRP, and IL-6 were significantly greater in patients 
than controls at both visits (Table 2).
Anthropometry and energy balance
Differences in anthropometric measurements between 
controls and patients at visit 1 and visit 2 are shown in 
(Table 3). Patients with RA had a significantly lower body 
weight and BMI than controls at both visits and body weight 
of patients increased significantly at visit 2. The difference 
between patients and controls was largely attributable to 
a lower FFM, although this did increase by an average of 
1 kg at visit 2 and was no longer significantly different from 
controls. Absolute values for REE in patients and controls 
were similar. However, when REE was corrected for FFM, 
patients had a significantly higher REE than controls at both 
visits. Energy and protein intake of patients was calculated 
to be at least as great as for controls (Table 4). Since half the 
patients recruited were taking prednisolone, we examined 
whether this might have an influence on the anthropometric or 
energy expenditure data, but there was no evidence for a sig-
nificant effect on any variable (data not shown).  Examining 
the correlation between IL-6 and anthropometric variables, 
BMI, FM, FFM, or REE revealed no statistically significant 
relationships, although the correlation for REE was 0.3 (95% 
CI = −0.05270 to 0.6195; P = 0.08) and lower REE values 
were not apparent at higher IL-6 concentrations (Figure 1).
Discussion
In contrast to simple starvation, where more than three-
quarters of the initial weight loss arises from reduction of 
Table  1 clinical  characteristics  of  study  subjects  with  Ra  at 
visits 1 and 2
Characteristics Visit 1 Visit 2 P value
number  16 16
Duration of Ra (y)  9.4 ± 7.6 –
no. tender joints  13.5 (±4.2) 5.8 (±5.1) ,0.01
no. swollen joints  13.6 ± 4.5 9.1 ± 4.0 0.02
Morning stiffness (h)  2.1 ± 1.2 1.2 ± 1.0 ,0.01
Patient assessment of disease  
activity (Vas; 0–10 cm)
7.0 ± 1.5 4.5 ± 4.6 ,0.01
Das 28 score 6.39 ± 0.8 5.23 ± 1.26 ,0.01
Physician assessment of disease  
activity (score [1–5])
2.8 ± 0.5 2.3 ± 1.0 0.03
mhaQ (0–3) 1.3 ± 0.5 0.9 ± 0.6 0.02
Vas pain (cm [0–10])  7.1 ± 1.8 5.1 ± 3 ,0.01
Mean prednisolone dose (mg)a 7.8 ± 3.4 8.1 ± 3.4 0.56
Notes: Values represent means ± sD (standard deviation);  a8/16 patients used 
steroids; Values are mean values of the 8 patients for visits 1 and 2; P was set at 
significant at 0.05.
Abbreviations: Das, disease activity score; mhaQ, modified health assessment 
Questionnaire; Ra, rheumatoid arthritis; Vas, visual analog score.
Table 2 laboratory measurements in patients with Ra at visits 1 and 2 compared with matched controls
Characteristic Patient visit 1 Patient visit 2 Controls P1 value visit 1 P2 value visit 2 P3 value visit 1 
vs visit 2
esR (mm/h) 46 (10–87) 46 (5–95) 8 (3–16) ,0.001 0.002 0.49
cRP (mg/l) 52 (7–108) 57 (3–224) 6 (4–9) ,0.001 0.001 0.39
Il-6 (pg/ml) 23 (2.7–82.5) 17 (2.7–56.6) 4 (1.9–7.2) 0.002 0.003 0.21
Notes: P1 (P value) patients in visit 1 visit compared with controls (Mann–Whitney); P2 (P value) patients in visit 2 compared with controls (Mann–Whitney); P3 (P value) 
patients in visit 1 compared with patients in visit 2 (Wilcoxon); all values are median (range).
Abbreviations: esR, erythrocyte sedimentation rate; cRP, c reactive protein; Il-6, interleukin-6.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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adipose tissue and only a small amount from loss of skeletal 
muscle,26 cachexia is characterized by depletion of lean body 
mass, with profound loss of skeletal muscle.27 This was 
apparent in the present study, where FFM was significantly 
lower in patients admitted to the study than healthy age- and 
sex-matched control subjects. All patients studied had very 
active disease, as reflected by their high DAS. At the visit 
2, when disease activity had reduced, there was a significant 
increase in weight, although this was accompanied by a fall 
in FM. The absence of a dramatic change in FFM or BMI 
between visits may reflect the fact that, although REE might 
change rapidly in relation to inflammatory disease activity, 
FFM would be expected to change relatively slowly, as a 
cumulative result of periods of changed disease activity and 
energy expenditure.
FFM is a major determinant of metabolic rate in nondiet-
ing subjects.28 However, lower FFM in patients, relative to 
controls, was not matched by significantly reduced REE. 
When REE was corrected for FFM, the energy expenditure per 
kg of FFM was significantly greater in patients than controls. 
This was most evident in patients at visit 1 but at visit 2 was 
not decreased significantly, compared with control values.
Since the energy intake of patients in the present study 
was not reduced, relative to controls, our findings are in 
accord with results of a study of patients following trauma 
or sepsis, in which dietary intake was not considered to play 
an important role in causing cachexia.29 Our study findings 
are consistent with the view that increased disease and meta-
bolic activity lead to accelerated FFM depletion in patients 
with RA. Accordingly, it seems reasonable to expect that the 
extent of cachexia in RA patients would be determined by a 
combination of intensity, duration, and frequency of active 
inflammatory disease. This analysis sheds some light on the 
possible sequence of events that culminate in the development 
of cachexia and may help explain the high prevalence of 
cachexia in RA. These results support and extend findings 
of a cross-sectional study of RA patients, which found that 
REE was higher in RA patients than controls.4
Higher IL-6 values in RA patients are well documented 
and, in the present study, this is also apparent. A cytokine-
driven increase in REE has been reported previously in animal 
studies30 and some association has been shown previously in 
RA4 although not in the context of IL-6. However, IL-6 has been 
implicated in the cachexia of cancer11 and some hematological 
Table 3 anthropometric and metabolic measurements in patients with Ra compared with matched controls
Characteristic Patient visit 1 Patient visit 2 Controls P1 value visit 1* P2 value visit 2* P3 value visit 1 
vs visit 2*
Weight (kg) 58.7 ± 7.1 59.4 ± 7.2   68.0 ± 13.7 0.01 0.01 ,0.01
height (cm) 160.7 ± 7.1 160.7 ± 7.1 162.5 ± 7.1 0.24 0.24 0.42
BMI (kg/ht[m2]) 22.7 ± 3.1 22.9 ± 3.1   25.5 ± 3.8 0.01 0.02 0.51
FM (kg) 33.6 ± 8.8 32.0 ± 9.3   36.6 ± 6.8 0.14 0.06 0.04
FFM (kg) 25.8 ± 10.1 26.8 ± 9.5   32.3 ± 10.9 0.04 0.07 0.11
Ree (kcal/day)  1407 ± 212 1378 ± 191  1388 ± 200 0.39 0.43 0.13
Ree/FFM (kcal/kg[ffm]/day) 62.2 ± 24.7 59.7 ± 26.3   46.0 ± 13.7 0.02 0.05 0.22
Notes: P1 (P value) patients in visit 1 compared with controls; P2 (P value) patients in visit 2 compared with controls; P3 (P value) patients in visit 1 compared with patients 
in visit 2; Values represent means ± sD (t test).
Abbreviations: BMI, body mass index; FM, fat mass; FFM, fat-free mass; Ree, resting energy expenditure.
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Figure 1 Relationship between interleukin-6 (Il-6) and resting energy expenditure 
(Ree) in patients with rheumatoid arthritis. The Il-6 and Ree were measured and 
results for both measures were available for 15 of 16 patients at each time point. 
The spearman correlation coefficient is 0.32 (P = 0.081).
Table  4  Dietary  energy  intake  in  patients  with  rheumatoid 
arthritis compared with controls
Patients Controls P value
energy intake  
(kcal/day)
1781 ± 701 1723 ± 517 0.47
energy intake/weight  
(kcal/kg/day)
30.3 ± 12.0 24.7 ± 7.4 0.12
Protein intake  
(g/day)
96.0 ± 23.0 70.0 ± 14.0 0.47
Protein intake  
g/kg/day
1.6 ± 0.3 1.0 ± 0.2 0.32
Note: Values represent means ± sD (t test).Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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disorders.31,32 The known IL-6 drive of metabolic activity, 
including an active hepatic acute phase protein response 
and hemopoetic responses, could reasonably be expected to 
contribute towards an increased REE and stimulus for protein 
to be mobilized from skeletal muscle. We did not in fact 
demonstrate a significant correlation between IL-6 and REE, 
although the P value (0.08) was close to the level chosen to 
demonstrate significance. Although a larger sample size may 
have resulted in a significant correlation, it is still notable that 
lower REE measurements were not seen when the plasma IL-6 
concentration increased, which may indicate that increased 
IL-6 is one of the factors associated with increasing low REE. 
The absence of a direct association between a reduction in 
IL-6 concentration and FFM is not surprising, given that FFM 
changes over a relatively long period, while IL-6 has a plasma 
half-life of a few minutes.
Whether some weight loss is inevitable in RA, or whether 
early aggressive nutritional support can prevent the occur-
rence of weight loss, requires further study. Evidence from 
other situations in which cachexia occurs suggests nutritional 
support may be only partially effective,33 although nutritional 
supplementation with fish oil has been shown to reverse 
weight loss in cancer cachexia and results in a fall in IL-6 
production.34 Other therapies, based on drugs to promote 
anabolism, might also play a future role. However, our data 
suggest that the most effective measure is likely to be control 
of inflammatory disease activity.
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